Poseida Therapeutics Announces Series A Financing

Poseida Therapeutics, Inc. (“Poseida”), a US-based, privately-held, human therapeutics company focused on the development of novel therapies using its ground-breaking proprietary genome engineering technologies, today announced that it has closed a Series A Preferred Stock financing. The lead investor, Malin Corporation plc. (“Malin”), an Irish-based global life sciences company, has agreed to contribute up to $30 million. The remainder of the financing round is comprised of a number of other investors.